Current development in toxicity, clinical trials guidelines for regulatory aspects of breast cancer nanomedicines

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985904%3A_____%2F20%3A00538083" target="_blank" >RIV/67985904:_____/20:00538083 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/B978-0-12-820016-2.00015-X" target="_blank" >http://dx.doi.org/10.1016/B978-0-12-820016-2.00015-X</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/B978-0-12-820016-2.00015-X" target="_blank" >10.1016/B978-0-12-820016-2.00015-X</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Current development in toxicity, clinical trials guidelines for regulatory aspects of breast cancer nanomedicines

Popis výsledku v původním jazyce

The existing challenges in breast cancer therapy and treatment has made researchers across the globe to come together and address the issues pertaining to existing therapy. Nanomedicine has emerged as an effective area in treatment of breast cancer therapy. However, toxicity issues of nanomaterial should be taken care of before going on further with clinical trials. In this regard, the countries and agencies have also formed some regulatory guidelines to be followed by scientist and researchers working in this field. The chapter focuses on some common nanomaterials employed for breast cancer therapy, their toxicity issues, possible reasons for causing toxicity, current innovative therapies for cancer treatment, and regulatory aspect of breast cancer nanomedicine.

Název v anglickém jazyce

Current development in toxicity, clinical trials guidelines for regulatory aspects of breast cancer nanomedicines

Popis výsledku anglicky

The existing challenges in breast cancer therapy and treatment has made researchers across the globe to come together and address the issues pertaining to existing therapy. Nanomedicine has emerged as an effective area in treatment of breast cancer therapy. However, toxicity issues of nanomaterial should be taken care of before going on further with clinical trials. In this regard, the countries and agencies have also formed some regulatory guidelines to be followed by scientist and researchers working in this field. The chapter focuses on some common nanomaterials employed for breast cancer therapy, their toxicity issues, possible reasons for causing toxicity, current innovative therapies for cancer treatment, and regulatory aspect of breast cancer nanomedicine.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Nanomedicines for Breast Cancer Theranostics

ISBN

978-0-12-820017-9

Počet stran výsledku

19

Strana od-do

351-369

Počet stran knihy

438

Název nakladatele

Elsevier

Místo vydání

Amsterdam

Kód UT WoS kapitoly

000561991600016